S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ENLV Enlivex Therapeutics Ltd

1.24

0.00 (0.00%)

Dec 22 2024 - Closed

Delayed by 15 minutes

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

null

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Enlivex Therapeutics Charts.

Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Enlivex Therapeutics Charts.

Enlivex Therapeutics Ltd News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 11 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Wednesday 11 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 3 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday 3 December 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 29 November 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 20 November 2024 (1 month ago) • Edgar (US Regulatory)

Enlivex Adopts Bitcoin Treasury Reserve Strategy
Wednesday 20 November 2024 (1 month ago) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Thursday 14 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday 12 November 2024 (1 month ago) • GlobeNewswire Inc.

More Enlivex Therapeutics Ltd News Articles

Asia Broadband (PK)

Anavex Life Sciences

Lightwave Logic

Digital Brand Media and ... (PK)

Elite Pharmaceuticals (QB)

Kraig Biocraft Laborator... (QB)

Fannie Mae (QB)

Northwest Biotherapeutics (QB)

Rennova Health (CE)

Tonix Pharmaceuticals

Code Green Apparel (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions